Tagged with AI

Pharma The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive medicines, how the agency’s role is evolving in response and in which ways the agency can collaborate with the industry.…

pharma The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with international partnerships, but an international institute that is based in France and how if there was one aspect he would…

Pharma  Country manager AbdelAziz Shaheen discusses Pfizer’s current and recent investments in Egypt, which include significant contributions to the continuous education of Egyptian pharmacists and health care professionals. With 54 years history in Egypt, expanding manufacturing operations, and ambitions to see Egypt to become a production hub for Africa, Pfizer Egypt is…

pharma Jan Smeitink, CEO of Khondrion, a young biotech company designing highly innovative solutions for people suffering from mitochondrial diseases, provides an overview of the latest developments regarding the company’s lead compound and explains how its talented team and strategic partnership with the Radboud University Medical Centre will help Khondrion to…

pharma The minister of health reveals how for the first time in the country´s history the healthcare sector is following a clear roadmap with the National Development Plan, a vision for where the country should be in 2030, how the National Health Initiative will mean a total reconstruction of the healthcare…

pharma Francisco García was appointed as the executive director for the Puerto Rico Manufacturers Association (PRMA) in August 2015. He stresses the importance of developing Puerto Rico’s entrepreneurial talent and startup clusters as his main initiatives. As you have recently taken over as executive director of PRMA, could you outline the…

pharma Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving today and the need to keep the momentum in the economic recovery. To start off, having joined the chamber recently,…

pharma Egypt is back in business, with economic growth and investor confidence in Egypt nearly back to levels seen in 2010, GDP growth up to four percent, and several high profile deals with multinationals. PharmaBoardroom spoke to Hisham A Fahmy, the CEO of the American Chamber of Commerce, about keeping Egypt…

Algeria PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable. Algeria’s youthful pharmaceutical landscape includes an array of state-controlled entities of an industrial or commercial nature alongside more conventional regulatory apparatus.  THE NATIONAL AGENCY FOR…

Pharma The Center for Pharmaceutical Engineering and Learning (CPEDaL) was established in 2006 as a ten year training program that is currently awaiting funding for the next five years. Carlos Velázquez, director of CPEDaL, explains how the Center introduces high school students to pharmaceutical engineering and their pioneering work in mixing…

pharma Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the pharmaceutical industry. To begin, Dr. Özgören, could you give us an overview of the intent behind the BioIzmir project? The…

Thailand Thailand is not traditionally known to be a manufacturing center due to its ever-changing policies, but OLIC (Thailand) Limited has risen as the nation’s number one contract manufacturing organization (CMO). OLIC’s managing director, Toyoyuki Kamide, talks about the company’s new manufacturing facility, its merger with Fuji Pharma, and its status…